Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;22(1):9-13.
doi: 10.1007/s40268-021-00376-x. Epub 2021 Dec 27.

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp

Matthew William McCarthy  1
Affiliations
Review

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp

Matthew William McCarthy. Drugs R D. 2022 Mar.

Abstract

On 2 June, 2021, the US Food and Drug Administration approved ibrexafungerp (formerly MK-3118 and SCY-078) for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection. Ibrexafungerp is the first drug approved in a novel antifungal class in more than two decades, and the Food and Drug Administration's decision was based on positive results from two pivotal phase III studies in which oral ibrexafungerp proved both safe and effective in patients with vulvovaginal candidiasis. The decision was also based on substantial preclinical and clinical work in both the pharmacokinetics and pharmacodynamics of ibrexafungerp. This paper reviews that research and looks ahead to explore how this novel antifungal agent may be used in the future to address the expanding problem of drug-resistant mycotic infections.

PubMed Disclaimer

Conflict of interest statement

Dr. McCarthy has nothing to declare and reports no conflicts of interests associated with this article.

References

    1. Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST) J Antimicrob Chemother. 2013;68(4):858–863. - PubMed
    1. Hector RF, Bierer DE. New β-glucan inhibitors as antifungal drugs. Expert Opin Ther Pat. 2011;21(10):1597–1610. - PubMed
    1. Denning DW. Echinocandins and pneumocandins: a new antifungal class with a novel mode of action. J Antimicrob Chemother. 1997;40(5):611–614. - PubMed
    1. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36(10):2950–2956. - PMC - PubMed
    1. Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45(Suppl. 3):56–60. - PubMed

LinkOut - more resources